Juan José Janer’s Post

View profile for Juan José Janer

Estudió en Colegio Europa, Malaga

Ankaferd Blood Stopper (ABS) and Epistaxis Can a topical agent stop a nosebleed in just 30 seconds? Epistaxis management just got a radical upgrade. Epistaxis is a common emergency, often distressing and potentially severe in clinical settings. The need for rapid, local, and efficient hemostasis is critical for patient comfort and time management. Traditionally, we've relied on agents like gelatin foam (GF) or combinations such as adrenaline plus lidocaine (AL) to control bleeding. But how fast is fast? A comparative study in an experimental epistaxis model evaluated the efficacy of Ankaferd Blood Stopper (ABS) against these agents. The results for the mean time to bleeding cessation were impressive and statistically significant: Ankaferd Blood Stopper (ABS): 30 seconds Adrenaline + Lidocaine (AL): 90 seconds Gelatin Foam (GF): 90 seconds Control (Saline Solution): 210 seconds Hemostasis time with ABS was significantly shorter than with AL and GF (P=0.002). Unlike agents that promote traditional fibrin formation, histopathological analysis suggests ABS acts through a unique mechanism: it induces the formation of a protein network and the aggregation of vital red blood cells that rapidly cover the bleeding area. This unique network formation is what allows it to act so quickly. For otolaryngologists and emergency teams: this means a topical agent that can control nosebleeds three times faster than common options. Otolaryngologists and Emergency Physicians: Nasal bleeding management is a fundamental skill. How would having a solution that reduces hemostasis time to 30 seconds change your epistaxis protocol? Share your experience or the most challenging hemostatic control application in your practice below! #AnkaferdBloodStopper #Epistaxis #Otolaryngology #EmergencyMedicine #ENT #Hemostasis #UrgentCare #SurgicalInnovation.

  • chart, bar chart, waterfall chart

To view or add a comment, sign in

Explore content categories